Screener
Revolution Medicines, Inc. RVMD Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Revolution Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-208969
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest expense | (12,197) | — |
| Change in fair value of warrant liability | (15,788) | 2,439 |
| Other expense, net | (117) | (10) |
| Total non-operating income (expense), net | (8,594) | 27,344 |
| Loss before income taxes | (453,816) | (213,416) |
| Net loss | $(453,816) | $(213,416) |
| Net loss per share attributable to common stockholders, basic and diluted | $(2.29) | $(1.13) |
| Weighted-average common shares used to compute net loss per share, basic and diluted | 198,098,047 | 188,145,904 |
Item 1. Financial Statements.
FAQ
- What is Revolution Medicines, Inc.'s other income (expense)?
- Revolution Medicines, Inc. (RVMD) reported other income (expense) of -$8.59M in Q1 2026.
- How has Revolution Medicines, Inc.'s other income (expense) changed year-over-year?
- Revolution Medicines, Inc.'s other income (expense) decreased by 131.4% year-over-year, from $27.34M to -$8.59M.
- What is the long-term trend for Revolution Medicines, Inc.'s other income (expense)?
- Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s other income (expense) has grown at a 177.4% compound annual growth rate (CAGR), from $917K to $54.33M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Revolution Medicines, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude